Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Antioxidant vitamin and mineral supplementation
4 evidence topics · 5 sources
Guideline recommendation for antioxidant supplementation in intermediate and advanced AMD
AREDS formulation and progression to advanced AMD
“Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AREDS2 formulation: lutein and zeaxanthin in place of beta carotene
“Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P = .04), mostly in former smokers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2
“Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote